Condition: Ischemic Stroke · Stroke · Stroke Acute · Sponsor: Emmanuel Carrera
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
This description comes directly from the study's public registry record.
Emmanuel Carrera, MD · +41 (0)22 372 83 18 · emmanuel.carrera@hug.ch
Nicolas Broc, MD · +41 (0)79 553 38 37 · nicolas.broc@hug.ch
Always discuss trial participation with your own doctor first.
| Geneva University Hospital | Geneva, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07080567